EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Comparative Efficacy and Safety of Delgocitinib Versus Topical Calcineurin Inhibitors for Atopic Dermatitis: A Systematic Review and Network Meta‐Analysis

Ruyu Yan, Shengli Chen, Jun Yan

Dermatologic Therapy · 2026-01 · 2026 (1)

DOI: 10.1155/dth/5327330 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Dermatologic Therapy, online erschienen am 13.07.2026. Verfasst von Ruyu Yan und 2 weiteren Autor:innen. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Delgocitinib is the first topical Janus kinase (JAK) inhibitor approved for atopic dermatitis (AD). However, its comparative efficacy against established calcineurin inhibitors (tacrolimus and pimecrolimus) remains unclear.

Objective

This systematic review and network meta‐analysis (NMA) aimed to evaluate the comparative efficacy and safety of topical delgocitinib versus tacrolimus and pimecrolimus in patients with AD.

Methods

We systematically searched PubMed, the Cochrane Library, and CNKI for randomized controlled trials (RCTs) comparing delgocitinib, tacrolimus, pimecrolimus, or vehicle in AD. Bayesian NMA was performed using the gemtc package in R (V4.3.1). Primary outcomes were Investigator’s Global Assessment (IGA) score of 0/1 (clear/almost clear) or ≥ 90% improvement in Physician’s Global Assessment (PGA). Secondary outcomes included Eczema Area and Severity Index (EASI), modified EASI (mEASI), body surface area (BSA), and adverse events (AEs).

Results

Twenty RCTs ( N = 5615) were included. Compared to vehicle, both delgocitinib 0.25% (odds ratio [OR]: 9.8, 95% credible interval [CrI]: 2.9–38) and 0.5% (OR: 11, 95% CrI: 3.2–39) demonstrated significant efficacy. Numerically, delgocitinib showed higher point estimates than tacrolimus 0.1% (OR: 5.7, 95% CrI: 2.8–12) and pimecrolimus 1% (OR: 3.1, 95% CrI: 1.9–5.4), but CrIs overlapped substantially across active treatments. No statistically significant superiority over active comparators was observed. The treatment effect was more pronounced in pediatric subgroups. Safety profiles were comparable across all active treatments.

Conclusions

Topical delgocitinib demonstrates numerically greater efficacy than tacrolimus and pimecrolimus in treating AD, with a comparable short‐term safety profile. However, indirect comparisons did not reveal statistically significant superiority over active comparators. These findings suggest delgocitinib as a promising nonsteroidal topical option, but direct head‐to‐head trials are needed to confirm its relative positioning.

Zitieren

APA

Yan, R., Chen, S., & Yan, J. (2026). Comparative Efficacy and Safety of Delgocitinib Versus Topical Calcineurin Inhibitors for Atopic Dermatitis: A Systematic Review and Network Meta‐Analysis. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/5327330

Vancouver

Yan R, Chen S, Yan J. Comparative Efficacy and Safety of Delgocitinib Versus Topical Calcineurin Inhibitors for Atopic Dermatitis: A Systematic Review and Network Meta‐Analysis. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/5327330

BibTeX
@article{Yan2026,
  author = {Yan, Ruyu and Chen, Shengli and Yan, Jun},
  title = {Comparative Efficacy and Safety of Delgocitinib Versus Topical Calcineurin Inhibitors for Atopic Dermatitis: A Systematic Review and Network Meta‐Analysis},
  journal = {Dermatologic Therapy},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/dth/5327330}
}
Kostenlos starten →